MNPR — what changed in the latest 10-Q
A section-by-section comparison of MNPR's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-12 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +34 | −9 | ~22 | 77 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +6 | −1 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-12
On May 19, 2026, Hepatology Communications published a peer-reviewed manuscript entitled “Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial.” The publication reported results from the Phase 2 ALXN1840-WD-204 study (NCT04573309) and demonstr…
Statistically significant reduction in daily copper balance from baseline, due to increased fecal copper excretion;
Mean daily copper balance change from baseline of -0.37 mg (p=0.005) during the 15 mg/day treatment period and -0.29 mg (p=0.023) through the overall study period;
Approximately 50% increase in the daily fecal copper output-to-intake ratio compared to baseline (p=0.041);
● Immediate increases in plasma total copper and directly measured non-ceruloplasmin-bound copper (dNCC), consistent with copper mobilization and formation of stable albumin tripartite complexes (ATCs) consisting of copper, ALXN1840, and albumin; and
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Based on recent regulatory interactions with the FDA regarding ALXN1840, during which the agency has encouraged continued dialogue with us on certain questions before we submit our NDA, we currently expect to submit our NDA in mid-2026. This anticipated timing reflects our efforts to incorporate add…
G&A expenses for the three months ended March 31, 2026, were $1,738,006, compared to $1,578,442 for the three months ended March 31, 2025. This represents an increase of $159,564 primarily attributed to (1) a $134,599 increase in G&A personnel expenses including stock-based compensation, and (2) a n…
Interest income for the three months ended March 31, 2026, was $1,332,203 compared to $596,845 for the three months ended March 31, 2025. The increase is attributed to interest earned on U.S. Treasury securities and commercial paper, and higher bank balances in 2026, due to the net proceeds of appro…
We have incurred losses and cumulative negative cash flows from operations since we commenced operations, resulting in an accumulated deficit of approximately $93.4 million as of March 31, 2026. We anticipate that we will continue to incur losses for the foreseeable future. We expect that our R&D an…
Effect of exchange rate and valuation changes on cash equivalents
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-12
On June 25, 2026, Quan Vu, our Chief Financial Officer, adopted a trading arrangement (the “Vu 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Vu Rule 10b5-1 Trading Plan provides for the sale of up…
On June 25, 2026, Chandler Robinson, our Chief Executive Officer, adopted a trading arrangement (the “Robinson 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Robinson Rule 10b5-1 Trading Plan provi…
On May 28, 2026, Christopher Starr, our Executive Chairman of the Board of Directors, adopted a trading arrangement (the “Starr 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Starr Rule 10b5-1 Trad…
On May 27, 2026, Kim Tsuchimoto, a member of the Board of Directors, adopted a trading arrangement (the “Tsuchimoto 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Tsuchimoto Rule 10b5-1 Trading Pla…
On May 27, 2026, Patrice Rioux, our Chief Medical Director, adopted a trading arrangement (the “Rioux 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). The Rioux Rule 10b5-1 Trading Plan provides for the …
Text removed vs the prior filing · source: 10-Q · 2026-05-14
During the quarter ended March 31, 2026, no non-employee director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice